The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities
CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:
Axion BioSystems’ Bioelectronic Assays Aid in the Development of Cancer Immunotherapies
Author: Axion Biosystems
The immunotherapy field is booming, with cell therapies like chimeric antigen receptor (CAR) T cells taking the lead. According to one forecast, the market is expected to reach $6.1 billion in size by 2030 for CAR-T therapies alone. The FDA approved the world’s first CAR-T therapy, Kymriah, in 2017, and it is now available at over 130 treatment centers across the United States. [Read more…]
Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics
In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies. [Read more…]
USPTO Issues New Patents for Cell Source’s Veto Cell Technology
Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections
March 19, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the Company”), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ transplants. In addition, Veto Cells can durably treat malignant and non-malignant blood diseases through active immune response management. Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. [Read more…]
